长江证券承销保荐有限公司 关于北京晶品特装科技股份有限公司 三、本次限售股上市流通的有关承诺 本次申请上市的限售股股东作出的有关承诺如下： 股东-军融汇智、军融创鑫、军融创富承诺： 1 首次公开发行部分限售股上市流通的核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"、"保荐机构"）作为 北京晶品特装科技股份有限公司（以下简称"晶品特装"、"公司"）持续督导 之保荐机构，根据《公司法》《证券法》《证券发行上市保荐业务管理办法》《上 海证券交易所科创板股票上市规则》以及《科创板上市公司持续监管办法》等有 关规定，对晶品特装首次公开发行部分限售股上市流通的事项进行了核查，并发 表如下意见： 一、本次上市流通的限售股类型 根据中国证券监督管理委员会2022年9月15日出具的《关于同意北京晶品特 装科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2022〕2133 号），公司首次向社会公开发行人民币普通股（A股）股票19,000,000股，并于 2022年12月8日在上海证券交易所科创板上市。公司首次公开发行A股股票后总 股本为75,659,066股，其中无限售条件流通股为17,458,759股，有限售 ...

Core Insights - The Robot ETF (159770) has seen significant trading activity, with a transaction volume of 178 million yuan as of November 27, 2025, and a notable increase in its scale and shares over the past week [1] - The Sci-Tech Innovation Index ETF Tianhong (589860) also performed well, with a trading volume of 23.52 million yuan and a strong increase in its tracked index [1] - The domestic open-source AI model, Tongyi Qianwen, has been adopted for a national-level project in Singapore, marking a significant breakthrough for Chinese open-source AI models in the global market [5] - The establishment of a standardization committee for humanoid robots in China is progressing, with key figures from leading companies appointed to important positions, indicating a move towards high-quality and large-scale development in the humanoid robot industry [6] Group 1: ETF Performance - The Robot ETF (159770) is the largest robot-themed ETF in the Shenzhen market, covering various segments of the robot industry, allowing investors to easily access the entire supply chain [2] - The Robot ETF has experienced a net inflow of 2.94 million yuan recently, with a total of 83.07 million yuan in net inflows over the past five trading days [1] - The Sci-Tech Innovation Index ETF Tianhong (589860) has a turnover rate of 7.51% and is designed to help investors capture opportunities in the technology growth market [2] Group 2: Industry Developments - The adoption of the Tongyi Qianwen model in Singapore's national AI strategy signifies the growing influence of Chinese open-source AI technologies in international markets [5] - The formation of the humanoid robot standardization committee in China is a crucial step towards establishing industry standards, which will enhance the competitive position of Chinese companies in the global humanoid robot sector [6]

Group 1 - The core point of the news is that Jingpin Special Equipment experienced a decline of 5.05% in stock price, reaching 76.55 CNY per share, with a total market capitalization of 5.792 billion CNY [1] - Jingpin Special Equipment focuses on the research, production, and sales of optoelectronic reconnaissance equipment and military robots, with its main business revenue composition being: special robots 39.03%, intelligent manufacturing 23.71%, simulation 18.99%, intelligent sensing equipment 16.16%, technical services 2.10%, and others 0.02% [1] Group 2 - According to data from the top ten heavy stocks of funds, one fund under Nuoan Fund holds a significant position in Jingpin Special Equipment, with 163,400 shares, accounting for 3.42% of the fund's net value, ranking as the eighth largest heavy stock [2] - The Nuoan Research Selected Stock Fund (320022) has a total scale of 423 million CNY and has achieved a return of 22.98% this year, ranking 1978 out of 4206 in its category [2]

Investment Rating - The report maintains a "Positive" investment rating for the defense and military industry [5] Core Viewpoints - The uncertainty in the Asia-Pacific situation is increasing, which may accelerate the equipment construction in China, focusing on new combat capabilities [2][12] - China's high-end aviation equipment showcased at the Dubai Airshow is expected to further expand the military trade market [12][15] - The Fujian aircraft carrier has conducted its first live training at sea, indicating a significant advancement in operational capabilities and technology [12][18] - The report emphasizes the importance of domestic demand for new combat capabilities and military trade as key growth areas [19] Summary by Sections Investment Suggestions and Targets - The report highlights various investment targets across different segments, including: - Engine and fuel chain: Companies like Xi'an Aero Engine (600893), Western Superconducting (688122), and others [19][20] - New quality and domains: Companies such as Aerospace Electronics (600879), Haige Communication (002465), and others [19][20] - Military electronics: Companies like Aerospace Electric (002025), Zhonghang Optical (002179), and others [19][20] - Military trade and main equipment: Companies such as AVIC Shenyang Aircraft (600760), AVIC Chengfei (302132), and others [19][20] Industry News and Market Performance - The report notes that the defense and military industry index has outperformed the broader market, with a decline of only -1.72% compared to the Shanghai Composite Index's -3.90% [22][25] - The report provides a detailed analysis of weekly market performance, indicating that the defense and military sector remains resilient amid broader market declines [22][25] Key Events and Developments - The report outlines significant recent events, including: - The U.S. government approved a new round of arms sales to Japan, which may heighten regional tensions and prompt China to expedite its military equipment development [12][9] - The successful live training of the Fujian aircraft carrier, showcasing advanced operational capabilities [12][18] - The participation of Chinese high-end military equipment in international exhibitions, enhancing China's presence in the global military trade market [12][15]

Core Viewpoint - Jingpin Special Equipment experienced a 5% decline in stock price, reaching 77.31 CNY per share, with a total market capitalization of 5.849 billion CNY as of the report date [1] Company Overview - Beijing Jingpin Special Equipment Technology Co., Ltd. was established on July 9, 2009, and went public on December 8, 2022. The company specializes in the research, production, and sales of optoelectronic reconnaissance equipment and military robots [1] - The revenue composition of the company includes: special robots 39.03%, intelligent manufacturing 23.71%, simulation and emulation 18.99%, intelligent sensing equipment 16.16%, technical services 2.10%, and others 0.02% [1] Shareholder Information - Among the top ten circulating shareholders of Jingpin Special Equipment, a fund under Huaxia Fund holds a significant position. The Huaxia CSI Robot ETF (562500) increased its holdings by 208,100 shares in the third quarter, totaling 1,029,000 shares, which represents 2.91% of the circulating shares [2] - The Huaxia CSI Robot ETF was established on December 17, 2021, with a current scale of 22.798 billion CNY. Year-to-date returns are 22.82%, ranking 2250 out of 4208 in its category, while the one-year return is 24.08%, ranking 1747 out of 3971 [2] Fund Management - The fund manager of Huaxia CSI Robot ETF is Hualong. As of the report date, Hualong has been in the position for 3 years and 92 days, managing total assets of 35.957 billion CNY. The best fund return during this period is 108.9%, while the worst return is -15.08% [3]

Core Viewpoint - The company plans to utilize idle raised funds for cash management, aiming to enhance the efficiency of fund usage and maximize shareholder returns while ensuring the safety of the funds [2][3][16]. Investment Overview - **Investment Purpose**: To improve the efficiency of raised funds and increase cash asset returns without affecting the normal implementation of investment projects [3]. - **Investment Amount**: The company intends to use up to RMB 600 million (including principal) of idle raised funds for cash management within 12 months from the board meeting approval [4][11]. - **Source of Funds**: The funds for cash management will come from temporarily idle raised funds from the company's initial public offering [5]. Investment Products - **Types of Investments**: The company will invest in high-security, liquid financial products, including but not limited to agreement deposits, structured deposits, time deposits, notice deposits, and large-denomination certificates of deposit [2][9]. - **Implementation Method**: After board approval, the management is authorized to make decisions regarding the selection of investment products and sign relevant legal documents [9]. Cash Management and Returns - **Return Distribution**: The income from cash management will be used primarily to cover any shortfall in investment amounts for projects and for the company's operational liquidity needs [9][16]. - **Recent Cash Management**: In the past 12 months, the company has also approved the use of up to RMB 650 million for cash management, indicating a consistent strategy to manage idle funds [10][11]. Risk Control Measures - **Risk Management**: The company will adhere to strict regulations and guidelines to ensure the safety of funds, including selecting reputable issuers and monitoring investment performance [15]. - **Supervision**: Independent directors and the audit committee will oversee the use of funds, with the option to hire professional auditors if necessary [15]. Impact on the Company - **Operational Impact**: The cash management initiative will not affect the company's daily operations or the progress of investment projects, aiming to enhance fund efficiency and shareholder returns [16][17]. - **Regulatory Compliance**: The cash management activities comply with relevant laws and regulations, ensuring no change in the intended use of raised funds [17][18].

Group 1 - Yongtai Technology's wholly-owned subsidiary has received approval for trial production of a lithium battery additive project with an annual capacity of 5,000 tons, set to begin trial production [1] - Mengke Pharmaceutical has decided to terminate its plan to issue shares to a specific entity due to ongoing disagreements among major shareholders, which could impact the company's stable operations [1] - Anhui Construction's subsidiary has been approved to register and issue debt financing tools totaling 15 billion yuan, including 5 billion yuan in short-term financing notes and 10 billion yuan in medium-term notes [2] Group 2 - Koli'er plans to repurchase shares worth between 10 million and 20 million yuan, with a maximum repurchase price of 20.94 yuan per share, to implement an employee stock ownership plan [2] - Xinhua Pharmaceutical has received approval for the production of fumaric acid volnoral raw materials, which are used to treat gastroesophageal reflux disease [3] - Lianhuan Pharmaceutical has received approval for additional specifications of tadalafil tablets, expanding its product offerings for treating erectile dysfunction and benign prostatic hyperplasia [5] Group 3 - Greenland Holdings reported an increase of 1,834 lawsuits with a total amount of 6.587 billion yuan from October 21 to November 13, 2025 [7] - Lianke Technology plans to invest up to 600 million yuan of idle funds in low-risk financial products [8] - Yinglian Co. signed a strategic procurement contract for 5,000 million square meters of composite aluminum foil with a leading new energy technology company [10] Group 4 - China Eastern Airlines reported a 10.58% year-on-year increase in passenger turnover for October, with a capacity increase of 6.84% [12] - China National Airlines reported an 8.7% year-on-year increase in passenger turnover for October, with domestic and international capacity also showing growth [15] - Oupai Home plans to use 320 million yuan of idle funds to purchase structured deposits with expected annual yields between 0.65% and 2.50% [16] Group 5 - Tianwei Food has submitted H-share issuance application materials to the Hong Kong Stock Exchange, which have been accepted by the China Securities Regulatory Commission [18] - Guizhou Aviation plans to establish a subsidiary focused on the research, production, and market expansion of intelligent automotive components, with initial operating funds of 40 million yuan [20] - Daimai Co. plans to invest 100 million yuan to establish a wholly-owned subsidiary in Shanghai focused on robotics technology [22] Group 6 - Founder Securities has received approval to issue company bonds totaling up to 30 billion yuan [24] - Hengrui Medicine has received clinical trial approvals for multiple drugs, indicating ongoing research and development efforts [26] - Zhaojing Pharmaceutical's product ZG006 has received orphan drug designation from the FDA, providing various benefits for its development in the U.S. market [39]

Group 1 - The company plans to use an amount not exceeding RMB 600 million of idle raised funds for cash management [1] - The usage period for the funds is set to be within 12 months from the approval date by the company's second board meeting [1] - The funds can be used in a rolling manner within the specified limit and timeframe [1]

长江证券承销保荐有限公司 关于北京晶品特装科技股份有限公司 使用部分闲置募集资金进行现金管理的 核查意见 长江证券承销保荐有限公司（以下简称"长江保荐"、"保荐机构"）作为 北京晶品特装科技股份有限公司（以下简称"晶品特装"、"公司"）首次公开 发行股票并在科创板上市持续督导的保荐机构，根据《证券发行上市保荐业务管 理办法》《上海证券交易所科创板股票上市规则》《科创板上市公司持续监管办 法（试行）》《上市公司募集资金监管规则》《上海证券交易所科创板上市公司 自律监管指引第1号——规范运作》等有关法律法规的规定，对公司拟使用最高 余额不超过6亿元（含本数）的部分闲置募集资金进行现金管理的事项进行了认 真、审慎的核查，核查情况及核查意见如下： 一、投资情况概述 （一）投资目的 在确保不影响募集资金投资项目正常实施以及确保募集资金安全的前提下， 提高募集资金的使用效率，增加公司现金资产收益，实现股东利益最大化。 注："累计投入进度"为统计至 2025 年 6 月 30 日的数据。 3、募集资金投资项目情况 （二）投资金额 本次拟使用额度不超过人民币 6 亿元（含本数）的部分闲置募集资金进行现 金管理，使用期限自公司 ...

北京晶品特装科技股份有限公司 关于使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：安全性高、流动性好的投资产品（包括但不限于协定性存 款、结构性存款、定期存款、通知存款、大额存单等） 投资金额：人民币 6 亿元（包含本数） 已履行及拟履行的审议程序：北京晶品特装科技股份有限公司（以下 简称"公司"或"晶品特装"）于 2025 年 11 月 14 日召开第二届董事会第十 五次会议，审议通过了《关于使用部分闲置募集资金进行现金管理的议案》， 公司保荐机构长江证券承销保荐有限公司（以下简称"保荐机构"或"长江 保荐"）出具了无异议的核查意见。该事项在董事会审批权限范围内，无须 提交股东会审议。 特别风险提示：尽管公司拟投资安全性高、流动性好的保本型投资产 品，投资风险可控。但金融市场受宏观经济影响较大，公司将根据经济形势 以及金融市场的变化适时适量介入，但不排除该项投资受到市场波动的影响， 存在一定的系统性风险。 一、投资情况概述 证券代码：688084 证券简称：晶品特 ...